Empowering Drug Development with Enhanced X-Ray Services
Improved Pharma has announced the expansion of its solid-state characterization services, which now include advanced X-ray diffraction and expert interpretation. This enhancement is a response to the increasing need for precise and defensible data in the pharmaceutical industry, specifically to strengthen market authorization applications and patents.
The Growing Need for Solid-State Characterization
As drug development evolves, it often involves complex small-molecule compounds that present challenges for accurate characterization. Issues arise with poorly crystalline, nanocrystalline, or disordered materials that are increasingly prevalent. Many laboratories may overlook the nuances of crystallography, but Improved Pharma adopts a comprehensive approach that integrates sophisticated in-house diffraction capabilities with the precision of synchrotron facilities, which are recognized for their cutting-edge research in this field.
Advanced Capabilities and Collaboration
Through a partnership with Argonne National Laboratory, Improved Pharma utilizes high-resolution synchrotron and PDF analysis techniques. These advanced tools allow for the definitive identification of crystal forms and the accurate characterization of materials that may often be misidentified by conventional laboratory methods. By ensuring that researchers have access to this high-level analysis, Improved Pharma reinforces the accuracy of research outcomes.
Meet the Experts Behind Enhanced Services
The expanded services are led by an expert team including Dr. Stephen Byrn and staff crystallographer Dr. Jared Smit. Their extensive experience enables the integration of high-performance in-house PXRD and SCXRD techniques. Coupled with additional data from Raman mapping, DSC, and TGA methodologies, Improved Pharma can produce comprehensive data packages. This multi-layered approach adheres to the highest standards required in today's Chemistry, Manufacturing, and Controls (CMC) submissions, as well as patent evaluations.
Statements from Leadership
Dr. Stephen Byrn, Chief Scientific Officer (CSO) at Improved Pharma, remarks on the critical nature of solid-state characterization in the modern pharmaceutical landscape. He highlights the growing trend of conducting essential studies in lower-cost environments that often prioritize speed over the necessary precision. This can lead to misidentifications and complications during stability assessments. He emphasizes that Improved Pharma aims to offer clients the scientific confidence that comes with top-tier data quality and detailed interpretations.
Dr. Pamela Smith, Chief Operating Officer (COO), underlines that operational excellence and high-quality data are fundamental to the service improvements. The integration of synchrotron sources and advanced data analysis into routine workflows reflects a commitment to enhancing client experiences, addressing common gaps in the global outsourcing landscape.
Key Features of the Enhanced Service
Improved Pharma's service enhancements include:
- Advanced in-house diffraction services combining high-performance PXRD and SCXRD data acquisition.
- Access to synchrotron radiation for high-resolution XRPD, aiding in trace phase detection.
- PDF analysis that leverages synchrotron data to differentiate amorphous materials from poorly crystalline substances.
- Comprehensive data integration that corroborates PXRD results with Raman mapping, solid-state NMR, and thermal analysis.
- Dedicated support tailored to meet the demands of regulatory submissions and patent reviews.
About Improved Pharma
Improved Pharma specializes in research, consulting, and information services aimed at enhancing pharmaceutical formulation and processes. Their offerings encompass solid-state studies, formulation design, analytical testing, and expert advice for the development and protection of intellectual property. Founded in 2006 by Stephen and Sarah Byrn, Improved Pharma continues to set the standard in pharmaceutical innovation.
Frequently Asked Questions
What improvements has Improved Pharma made to its services?
Improved Pharma has expanded its solid-state characterization services to include advanced X-ray diffraction and expert interpretation, enhancing data quality for market authorization applications.
Who leads the Enhanced X-Ray Services at Improved Pharma?
The enhanced services are led by experts including Dr. Stephen Byrn and Dr. Jared Smit, who bring extensive experience in crystallography.
Why is solid-state characterization important?
It is crucial for defining the manufacturable form of drug substances, supporting regulatory submissions, and ensuring accurate patent applications.
What technologies does Improved Pharma use in their analyses?
They utilize advanced techniques such as PXRD, SCXRD, Raman mapping, DSC, TGA, and synchrotron sources for precise characterizations.
When was Improved Pharma founded?
Improved Pharma was founded in 2006 by Stephen and Sarah Byrn, with a mission to enhance pharmaceutical processes and formulations.
